PMID- 25228230
OWN - NLM
STAT- MEDLINE
DCOM- 20150603
LR  - 20220310
IS  - 1423-0216 (Electronic)
IS  - 1021-7401 (Linking)
VI  - 22
IP  - 1-2
DP  - 2015
TI  - The safety of low-dose glucocorticoids in rheumatic diseases: results from 
      observational studies.
PG  - 72-82
LID - 10.1159/000362727 [doi]
AB  - Glucocorticoids (GC) remain the most commonly used agents for managing 
      inflammatory rheumatic diseases. The adverse effects (AEs) associated with 
      high-dose GCs are well established, but there is a widespread misconception that 
      AEs of high-dose GC therapy (>30 mg of prednisone or equivalent daily) are 
      similar in low-dose therapy (</=7.5 mg of prednisone equivalent a day). Although 
      high-quality evidence on AEs of low-dose GC therapy is still incomplete, risks 
      and safety of low-dose GC therapy in rheumatic diseases are reviewed based on 
      current evidence by category, including musculoskeletal, cardiovascular, 
      infectious, gastrointestinal, neuropsychiatric, endocrine and metabolic, 
      dermatologic, and ophthalmologic AEs. Recommendations concerning monitoring AEs 
      with low-dose GC therapy are provided for each category of AEs on the basis of 
      our literature review and clinical experience. There is emerging evidence that 
      low-dose GCs are associated with a much lower level of AEs, which would allow 
      their use over long periods in patients with rheumatic disease who gain clinical 
      effectiveness and well-being from their use. Nonetheless, knowledge and 
      understanding of AEs from low-dose GCs is vital to maximize benefits and minimize 
      risks to patients.
CI  - (c) 2014 S. Karger AG, Basel.
FAU - Hwang, Yong Gil
AU  - Hwang YG
AD  - Division of Rheumatology and Clinical Immunology, University of Pittsburgh, 
      Pittsburgh, Pa., USA.
FAU - Saag, Kenneth
AU  - Saag K
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140912
PL  - Switzerland
TA  - Neuroimmunomodulation
JT  - Neuroimmunomodulation
JID - 9422763
RN  - 0 (Anti-Arrhythmia Agents)
RN  - 0 (Glucocorticoids)
SB  - IM
MH  - Anti-Arrhythmia Agents/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Glucocorticoids/*adverse effects
MH  - Humans
MH  - Hypertension/chemically induced
MH  - Male
MH  - Mood Disorders/chemically induced
MH  - Muscular Diseases/chemically induced
MH  - Observational Studies as Topic
MH  - Osteoporosis/chemically induced
MH  - Rheumatic Diseases/*drug therapy/genetics
EDAT- 2014/09/18 06:00
MHDA- 2015/06/04 06:00
CRDT- 2014/09/18 06:00
PHST- 2014/09/18 06:00 [entrez]
PHST- 2014/09/18 06:00 [pubmed]
PHST- 2015/06/04 06:00 [medline]
AID - 000362727 [pii]
AID - 10.1159/000362727 [doi]
PST - ppublish
SO  - Neuroimmunomodulation. 2015;22(1-2):72-82. doi: 10.1159/000362727. Epub 2014 Sep 
      12.